[Splenectomy as definitive surgical treatment for hemophagocytic lymphohistiocytosis].

José Luis Beristain-Hernández, Arni Alejandro Mendoza-Soto, María de Los Ángeles Macías-Clavijo
{"title":"[Splenectomy as definitive surgical treatment for hemophagocytic lymphohistiocytosis].","authors":"José Luis Beristain-Hernández, Arni Alejandro Mendoza-Soto, María de Los Ángeles Macías-Clavijo","doi":"10.5281/zenodo.10278159","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hemophagocytic syndrome or hemophagocytic lymphohistiocytosis (HL) is an immune hyperactivation of multifactorial etiology, characterized by excessive activation of lymphocytes and macrophages, as well as numerous pro-inflammatory cytokines. It has a non-specific and highly variable clinical presentation, with splenomegaly being one of the clinical manifestations. Due to its nature, it can manifest during childhood or adult life, which is why it is a disease of diagnostic and therapeutic complexity.</p><p><strong>Clinical case: </strong>38-year-old male patient without comorbidities, who presented with abdominal pain, choluria, fever > 38 °C and diaphoresis of more than 10 days of evolution. A bone marrow aspirate was performed as part of the diagnostic approach with data compatible with hemophagocytosis and cytopenias. The immunosuppressive management did not show the expected response, which is why an open splenectomy was performed as the last therapeutic option with adequate hematological control. A documentary review of the disease was carried out, and of the therapeutic options, emphasizing surgical management in case of refractoriness to medical treatment.</p><p><strong>Conclusions: </strong>Splenectomy increases the overall survival rate and the time free of HL progression, even though there are still no studies to determine with certainty the ideal time to perform a splenectomy in patients with pancytopenia without splenomegaly who suffer from hemophagocytic syndrome.</p>","PeriodicalId":94200,"journal":{"name":"Revista medica del Instituto Mexicano del Seguro Social","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista medica del Instituto Mexicano del Seguro Social","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5281/zenodo.10278159","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hemophagocytic syndrome or hemophagocytic lymphohistiocytosis (HL) is an immune hyperactivation of multifactorial etiology, characterized by excessive activation of lymphocytes and macrophages, as well as numerous pro-inflammatory cytokines. It has a non-specific and highly variable clinical presentation, with splenomegaly being one of the clinical manifestations. Due to its nature, it can manifest during childhood or adult life, which is why it is a disease of diagnostic and therapeutic complexity.

Clinical case: 38-year-old male patient without comorbidities, who presented with abdominal pain, choluria, fever > 38 °C and diaphoresis of more than 10 days of evolution. A bone marrow aspirate was performed as part of the diagnostic approach with data compatible with hemophagocytosis and cytopenias. The immunosuppressive management did not show the expected response, which is why an open splenectomy was performed as the last therapeutic option with adequate hematological control. A documentary review of the disease was carried out, and of the therapeutic options, emphasizing surgical management in case of refractoriness to medical treatment.

Conclusions: Splenectomy increases the overall survival rate and the time free of HL progression, even though there are still no studies to determine with certainty the ideal time to perform a splenectomy in patients with pancytopenia without splenomegaly who suffer from hemophagocytic syndrome.

[脾切除术作为嗜血细胞淋巴组织细胞增多症的最终外科治疗方法]。
背景:嗜血细胞综合征或嗜血细胞淋巴组织细胞增生症(HL)是一种多因素致病的免疫功能亢进症,其特征是淋巴细胞和巨噬细胞过度活化,以及大量促炎细胞因子。该病的临床表现非特异性且多变,脾脏肿大是其临床表现之一。由于其性质,它可以在儿童期或成年期发病,因此是一种诊断和治疗复杂的疾病:38 岁男性患者,无合并症,因腹痛、胆汁淤积、发热 > 38 °C、全身湿疹超过 10 天而就诊。在诊断过程中进行了骨髓穿刺,结果显示与嗜血细胞增多症和细胞减少症相符。免疫抑制治疗没有显示出预期的效果,因此在充分控制血液病的情况下,最后选择了开放性脾切除术。对该疾病和治疗方案进行了文献回顾,强调在药物治疗无效的情况下应采取手术治疗:脾切除术可提高总生存率,延长无 HL 进展的时间,尽管目前仍无研究明确确定对患有嗜血细胞综合征的泛发性无脾肿大患者实施脾切除术的理想时间。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信